B-Cell Malignancies
This educational resource is intended to provide health care professionals with the latest knowledge on the therapeutic advances in B-cell malignancies with a special focus on Bruton’s tyrosine kinase inhibitors (BTKi) so that HCPs provide individualized treatment strategies that optimize outcomes for patients with B-cell malignancies.
This resource utilizes the expertise of an independently selected editorial panel who are specialists in the field of haematological cancers.
Infographics
These infographics cover the latest information on the role of BTK inhibitors in the treatment of B-cell malignancies, specifically at the mechanisms of action across the different BTKis, the safety/efficacy profiles of these molecules, and any potential adverse effects and toxicities associated with the prolonged use of BTKis, as well as how to identify early signs of resistance and treatment failure and understand potential mechanisms of resistance to adapt treatment plans accordingly.
Articles
A specially curated list of peer-reviewed articles discussing the latest advancements in treatment of B-cell malignancies.
On-Demand Webinars
These CME accredited webinars provide information that will aid health care professionals to learn about:
- The spectrum of B-cell cancers and their molecular heterogeneity
- Bruton’s Tyrosine Kinase inhibitors in the treatment of B-cell cancers
- The role of BTKis in the treatment of B-cell malignancies, and differences between their mechanisms of action
- The safety/efficacy profile and potential adverse effects and toxicities associated with the prolonged use of BTKis
This will help HCPs to optimize the treatment outcomes for patients with B-cell malignancies and inform them on how to identify early signs of resistance and treatment failure and understand potential mechanisms of resistance to adapt treatment plans accordingly.
Stay Up To Date
Join the Wiley Knowledge Hub mailing list to stay up to date with the latest research and education in your area of interest.